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Patients with inflammatory bowel disease are at increased risk for colon cancer due to
augmented oxidative stress. These patients also have compromised antioxidant defenses
as the result of nutritional deficiencies. The micronutrient selenium is essential for
selenoprotein production and is transported from the liver to target tissues via selenoprotein
P (SEPP1). Target tissues also produce SEPP1, which is thought to possess an
endogenous antioxidant function. Here, we have shown that mice with Sepp1
haploinsufficiency or mutations that disrupt either the selenium transport or the enzymatic
domain of SEPP1 exhibit increased colitis-associated carcinogenesis as the result of
increased genomic instability and promotion of a protumorigenic microenvironment.
Reduced SEPP1 function markedly increased M2-polarized macrophages, indicating a role
for SEPP1 in macrophage polarization and immune function. Furthermore, compared with
partial loss, complete loss of SEPP1 substantially reduced tumor burden, in part due to
increased apoptosis. Using intestinal organoid cultures, we found that, compared with those
from WT animals, Sepp1-null cultures display increased stem cell characteristics that are
coupled with increased ROS production, DNA damage, proliferation, decreased cell
survival, and modulation of WNT signaling in response to H2O2-mediated oxidative stress.
Together, these data demonstrate that SEPP1 influences inflammatory tumorigenesis by
affecting genomic stability, the inflammatory microenvironment, and epithelial stem cell
functions.
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Introduction
Inflammatory bowel disease (IBD) primarily comprises two 
types of chronic inflammatory disorders of the intestine: 
Crohn’s disease and ulcerative colitis. IBD affects approxi-
mately 1.4 million Americans, with typical onset occurring at 
between 15 and 30 years of age (1). While the etiology of IBD is 
incompletely understood, prevailing thought presents a model 
in which the interplay of (a) intestinal microbiota or other unde-
fined environmental exposures, (b) genetic susceptibility, and 
(c) inappropriately sustained and severe autoimmune inflam-
matory responses leads to repetitive injury of the GI tract, 
resulting in a protumorigenic microenvironment rich in ROS 
and reactive nitrogen species that predisposes to colon cancer 
(2, 3). Colitis-associated cancer (CAC) risk in IBD is influenced 
by several factors, including age of diagnosis, disease extent, 
and severity of inflammation (4–8). Importantly, as increased 
disease activity is associated with increased cancer risk, under-
standing modifiers of IBD severity and CAC risk factors is of 
paramount importance.
Selenium is a trace element that is specifically incorporated 
into selenoproteins as selenocysteine through a specialized 
UGA codon encoded in the mRNA. Selenium deficiency results 
in stimulation of the WNT and NRF2 pathways (9–11), which 
are both heavily implicated in the pathogenesis of colon cancer 
(12–14). Selenoproteins are enzymes that participate in oxidative 
defense and are thought to protect against colon cancer, espe-
cially in settings of high oxidant stress, such as chronic inflam-
matory states. Several epidemiological studies have inversely 
correlated nutritional selenium status and cancer risk, particu-
larly in colon cancer (15). Recently, our laboratory has demon-
strated that selenium deficiency in mice exacerbates intestinal 
injury in response to chemical models of colitis and increases 
tumorigenesis in CAC modeling (16).
Selenoprotein P (SEPP1) is a major selenoprotein and is 
thought to serve two main roles: supplying tissues with selenium 
and acting in an antioxidant defense capacity. The transport 
role is carried out by the C-terminal domain of SEPP1, which 
contains 9 selenocysteine residues (17, 18). The antioxidant role 
is carried out by a single selenocysteine within a UXXC redox 
motif at amino terminal residues 40–43 (19), a domain that has 
recently been shown to have peroxidase activity (20). As seleno-
proteins are produced in a hierarchical manner based on sele-
nium availability, the importance of SEPP1 is underscored by the 
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of mice subjected to chronic DSS administration using the murine 
endoscopic index of colitis severity (MEICS) scoring system (27) 
revealed increased injury in response to DSS after 3 cycles (8.1 ± 
0.4 vs. 4.1 ± 0.5 MEICS score, P < 0.0001; Figure 1E). Furthermore, 
chronic DSS treatment led to increased ACF formation in Sepp1–/– 
mice compared with that in both WT and Sepp1+/– mice (Sepp1–/–, 
3.2 ± 0.4 in tumors per colon vs. Sepp1+/–, 2.1 ± 0.3, and WT, 1.9 ± 
0.3 tumors per colon, P < 0.05; Figure 1E), suggesting that com-
plete SEPP1 loss exacerbates injury and tumorigenesis in response 
to DSS. In addition, Sepp1–/– mice demonstrated decreased prolif-
eration after chronic DSS treatment in comparison with that of 
Sepp1+/– and WT mice (Figure 1E), with no differences in apoptosis 
(data not shown) among the cohorts.
SEPP1 is a haploinsufficient tumor suppressor in inflammatory 
carcinogenesis. Based on the impact of SEPP1 loss on initiation 
in response to AOM and DSS as single modalities, we predicted 
that SEPP1 would play a critical role in ensuring tumor cell sur-
vival after inflammatory injury. We used a CAC model in which 
WT, Sepp1+/–, and Sepp1–/– mice received AOM and repeated-dose 
DSS (AOM/DSS). As expected, complete loss of SEPP1 decreased 
colonic selenium content (Figure 2A), though we noted that this 
decrease was modest, indicating that SEPP1 is not the only mech-
anism of selenium supply in the colon. Complete loss of SEPP1 led 
to a decrease in tumor multiplicity (2.7 ± 0.7 in Sepp1–/– vs. 5.2 ± 0.8 
tumors per mouse in WT, P = 0.02; Figure 2, B and C) and altera-
tion in tumor size in Sepp1–/– mice compared with that in Sepp1+/– 
mice but not WT mice (2.5 ± 0.4 in Sepp1–/– vs. 4.2 ± 0.5 mm2 in 
Sepp1+/–, P = 0.01; Figure 2, B and D), suggesting that complete loss 
of SEPP1 impaired survival or proliferation of initiated epithelial 
cells. In contrast, partial loss of SEPP1 led to increased tumor mul-
tiplicity (8.3 ± 1.2 in Sepp1+/– vs. 5.2 ± 0.8 tumors per mouse in WT, 
P = 0.03; Figure 2, B and C) but no change in tumor size. However, 
histopathological examination suggested more advanced dyspla-
sia in the Sepp1+/– mice (Figure 2E).
The decrease in tumorigenesis in the Sepp1–/– mice was con-
comitant with increased apoptosis, as measured by TUNEL stain-
ing (74.4 ± 10.9 vs. 34.3 ± 3.1 TUNEL+ cells per tumor high-power 
field [HPF] in WT, P < 0.01; Figure 3A, left, and Supplemental Fig-
ure 2, A and B, top) and Western blotting for markers within the 
intrinsic apoptosis pathway (Figure 3A and Supplemental Figure 
2B, bottom). Therefore, we hypothesized that decreased tumor 
multiplicity might be caused in part by clearance of initiated cells 
due to oxidative injury beyond that which total SEPP1 loss can 
compensate. This phenomenon has been hypothesized to play 
a role in the initiation process of many cancers and was recently 
demonstrated in the process of ferroptosis, a mechanism of cell 
death triggered via the production of iron-dependent ROS (28, 
29). Moreover, proliferation was increased in Sepp1+/– tumors (85.9 
± 2.9 vs. 55.6 ± 2.8 Ki67+ cells per tumor HPF in WT, P < 0.0001; 
Figure 3B and Supplemental Figure 2D) and decreased in Sepp1–/– 
tumors (19.0 ± 6.9 vs. 55.6 ± 2.8 Ki67+ cells per tumor HPF in WT, 
P < 0.0001; Figure 3B and Supplemental Figure 2D) and crypts 
(1.6 ± 0.2 vs. 4.6 ± 0.2 Ki67+ cells per crypt in WT, P < 0.0001; Sup-
plemental Figure 2C). These data support a role for clearance of 
initiated cells in Sepp1–/– tumors.
Intratumoral DNA damage increases in a dose-dependent 
manner with decreased SEPP1 levels. Selenium has been identi-
fact that, even under conditions of severe selenium deficiency, 
its production perseveres (19). Previous studies have shown that 
SEPP1 is downregulated in colorectal cancers (CRCs) (21) and 
SNPs within the gene are associated with advanced adenoma 
risk (22). Because SEPP1 serves as the major selenium transport 
protein, the known effects of selenium on WNT and NRF2 sig-
naling in target tissues may partially depend on SEPP1. The anti-
oxidant function of SEPP1 also suggests that it could play a role 
in cancer prevention, particularly in the context of inflamma-
tory cancers characterized by increased oxidative stress, such 
as CAC (23). Indeed, the gastrointestinal tract is susceptible to 
oxidative damage resulting from direct contact of the colonic 
epithelium with microbial and food-derived ROS, and the loss 
of SEPP1 might result in increased oxidative damage–induced 
tumor initiation in the colonic mucosa. This potential damage is 
augmented in the context of IBD, during which oxidative stress 
plays a major role (23). Thus, SEPP1 may regulate stem cell path-
ways and protect from CAC.
In the present study, we investigated the role of SEPP1 in 
colonic epithelial biology and how its loss affects colitis-associ-
ated carcinoma. We demonstrate that SEPP1 loss contributes to 
increases in colonic epithelial stem cell properties and modula-
tion of WNT tone and, in response to oxidative stress, decreases 
cell survival and increases oxidative DNA damage in intestinal 
organoids. These SEPP1-dependent phenotypes ultimately con-
tribute to an increase in inflammatory tumorigenesis with Sepp1 
heterozygosity or upon loss of either the redox-active site or the 
selenium transport domain of SEPP1. SEPP1 manipulation was 
found to alter the tumor microenvironment and genomic integ-
rity. Our findings establish a critical role for SEPP1 in intestinal 
biology, homeostasis, injury response, preservation of genomic 
integrity, and inflammatory carcinogenesis.
Results
Loss of SEPP1 enhances both tumor promotion and initiation. 
Because SEPP1 mRNA expression is decreased as early as the 
adenoma stage in CRC (ref. 24 and Supplemental Figure 1A; sup-
plemental material available online with this article; doi:10.1172/
JCI76099DS1) and in tumors of mice subjected to an inflamma-
tory carcinogenesis protocol (Supplemental Figure 1B), we pre-
dicted that SEPP1 loss would enhance tumorigenesis. In order 
to test the impact of SEPP1 loss on tumor initiation and promo-
tion, respectively, we used both a 6-month azoxymethane (AOM) 
protocol (Figure 1A) and a chronic dextran sodium sulfate (DSS) 
administration protocol (Figure 1B). AOM is a procarcinogen 
that is metabolically activated to a potent alkylating agent form-
ing O6-methyl-guanine (25). DSS serves as a tumor-promoting 
agent, and repeated DSS administration produces chronic colonic 
inflammation (26). To determine whether SEPP1 deletion influ-
ences colonic tumorigenesis, we used Sepp1–/– mice. These mice 
are globally null for SEPP1, and a lack of expression could be seen 
in both the Sepp1–/– colon and small intestine as compared with 
WT mice (Figure 1C). Methylene blue staining of colons 6 months 
after AOM administration revealed an increase in aberrant crypt 
foci (ACF) in Sepp1–/– mice compared with that in WT mice (6.0 ± 
0.6 vs. 2.5 ± 0.3 ACF per colon, P < 0.001; Figure 1D), indicating a 
role for SEPP1 loss in tumor initiation. Endoscopic injury analysis 
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tumor microenvironment, decreasing Sepp1 expression leads to 
an increase in oxidative DNA damage.
Protumorigenic M2 macrophage polarization is increased in 
Sepp1+/– tumors. The most significantly induced gene after polar-
ization of macrophages to the M2 phenotype is SEPP1 (32–34). 
Moreover, proinflammatory cytokines induce iNOS, which results 
in downregulation of SEPP1 (35). To determine whether SEPP1 
influences macrophage phenotypes and inflammation, we ana-
lyzed tumors from WT, Sepp1+/–, and Sepp1–/– mice after AOM/DSS 
treatment for macrophage polarization. Immunohistochemistry of 
tumors for the pan-macrophage marker F4/80 and either the M1 
macrophage marker IL-1β or the M2 macrophage marker argin-
ase I (Arg1) revealed an increase of total macrophages in Sepp1+/– 
fied as a potential contributor to the maintenance of genomic 
stability (30, 31). However, the role of SEPP1 in DNA damage 
repair is unknown. We wanted to test the impact of SEPP1 defi-
ciency on crypt and intratumoral DNA damage. 8-hydroxygua-
nine (8-OHdG) staining, a measure of oxidative DNA damage, 
demonstrated that intratumoral DNA damage increases with 
decreased Sepp1 expression (WT: 8.1 ± 0.8 8-hydroxyguanine+ 
cells per tumor HPF, Sepp1+/–: 15.3 ± 1.5, 8-hydroxyguanine+ cells 
per tumor HPF, P = 0.002; Sepp1–/–: 23.3 ± 3.4 8-hydroxyguanine+ 
cells per tumor HPF, P = 0.0007; Figure 3C and Supplemental 
Figure 2F), though crypt DNA damage was not altered when 
compared with that of WT mice in response to SEPP1 deficiency 
(Supplemental Figure 2E). These data suggest that, within the 
Figure 1. Absence of SEPP1 exacerbates tumorigenesis in response to AOM and injury after chronic DSS treatment. (A) Schematic of the AOM protocol 
used. Mice were injected with AOM and aged for 6 months before being sacrificed on day 180 after AOM treatment. (B) Schematic of the chronic DSS 
protocol used. Mice were subjected to three 5-day cycles of 3% DSS ad libitum. There were 16 days of recovery between each DSS administration, and 
mice were monitored for injury by endoscopy (black circles) 4 days after each DSS cycle (gray rectangles). (C) Immunofluorescent staining of SEPP1 (red) 
within the colons and small intestines of WT and Sepp1–/– mice (original magnification, ×100). (D) ACF counts per mouse in WT (n = 4), Sepp1+/– (n = 4), 
and Sepp1–/– (n = 3) mice subjected to the AOM protocol. (E) Endoscopic colitis score, ACF counts, and Ki67 staining in mice subjected to the chronic DSS 
protocol (7, WT; 10, Sepp1+/–; 10, Sepp1–/–). *P < 0.05, **P < 0.01, ***P < 0.001, 1-way ANOVA, Newman-Keuls multiple comparison test.
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tribute to a protumorigenic microenvi-
ronment in these mice.
Loss of the selenium-rich C-terminal 
domain of SEPP1 promotes inflamma-
tory tumorigenesis. SEPP1 is considered 
to be a selenium transport protein, and 
deletion of the selenium-rich C-termi-
nal domain (Sepp1Δ240–361/Δ240–361) results 
in severe selenium deficiency in the 
brain and testes of mice (36). Colonic 
selenium levels were also decreased in 
Sepp1Δ240–361/Δ240–361 mice (394.5 ± 19.6 
vs. 260.2 ± 10.6 ng selenium/g colon, 
P = 0.0001; Figure 5A), yet the presence 
of selenium suggests that, while SEPP1 
contributes to selenium delivery to the 
colon, it is not the sole source. Because 
selenium has been implicated in DNA 
damage repair via regulation of p53 (37), 
WNT and NRF2 signaling, and modifi-
cation of several cancer types, including 
colorectal, lung, laryngeal, hepatic, and 
prostate (38–41), we determined whether 
the loss of the selenium-rich domain of SEPP1 would contribute to 
tumorigenesis. We subjected WT and Sepp1Δ240–361/Δ240–361 mice to the 
AOM/DSS protocol and analyzed them for tumor burden. We found 
that SEPP1 truncation resulted in an increase in tumor number (7.9 
± 1.4 vs. 3.9 ± 0.7 tumors per mouse, P = 0.02; Figure 5B). We have 
previously determined that selenium deficiency results in increased 
dysplasia grade in this model (16). Similarly, tumor grade was more 
advanced in Sepp1Δ240–361/Δ240–361 mice (P < 0.05; Figure 5C).
Along with an increase in tumor number, we also observed an 
increase in intratumoral proliferation (20.3 ± 2.2 vs. 13.4 ± 1.7 Ki67+ 
cells per tumor HPF, P = 0.04; Figure 5D and Supplemental Figure 
3A) but no change in crypt proliferation (Supplemental Figure 5A) or 
crypt or tumor apoptosis (Supplemental Figure 4, B and C). Consis-
tent with a role of selenium in DNA damage, there was an increase 
in crypt (1.0 ± 0.08 vs. 0.7 ± 0.04 8-OHdG+ cells per crypt, P = 0.02; 
Figure 5E and Supplemental Figure 3B) and intratumoral (29.8 ± 2.8 
vs. 17.1 ± 2.7 8-OHdG+ cells per tumor HPF, P = 0.01; Figure 5F and 
Supplemental Figure 3C) DNA damage index scores in mice lacking 
the selenium-rich C-terminal domain compared with that in WT 
mice. These data suggest that the selenium-rich domain of SEPP1 
tumors (WT: 13.1 ± 1.3, Sepp1+/–: 23.2 ± 3.0, P < 0.01, Sepp1–/–: 13.1 
± 0.8 F4/80+ cells per tumor HPF; Figure 4A), apparently result-
ing from an increased M2 macrophage presence (WT: 8.4 ± 0.8, 
Sepp1+/–: 18.0 ± 3.9, Sepp1–/–: 8.3 ± 1.1 F4/80+/ARG1+ cells per tumor 
HPF; Figure 4C), as M1 macrophage numbers remain unaltered 
(Figure 4B). Interestingly, Sepp1–/– tumors did not demonstrate 
increased M2 polarized macrophage infiltration. In order to deter-
mine whether this effect was due to recruitment or polarization, we 
isolated bone marrow macrophages from WT, Sepp1+/–, and Sepp1–/– 
mice and treated them with IFN-γ and LPS to polarize to the M1 
phenotype and IL-13 to polarize to the M2 phenotype. Analysis of 
M1 markers Inos and Il1b demonstrated decreased M1 polarization 
in Sepp1+/– macrophages (Inos: 19,494 ± 593.8 vs. 14,961 ± 782.3 fold 
change, P < 0.001; Il1b: 337.6 ± 0.78 vs. 225.1 ± 20.66 fold change, 
P < 0.001; Figure 4D), while the M2 marker Ym1 indicated increased 
polarization to M2 (13.1 ± 3.3 vs. 26.6 ± 0.3, P < 0.001; Figure 4E). 
These data indicate that Sepp1 haploinsufficiency leads to altered 
macrophage polarization upon directed stimulation, a phenotype 
observed in vivo in the inflammatory infiltrates in Sepp1+/– tumors. 
Therefore, it is possible that altered immune responses may con-
Figure 2. Sepp1 haploinsufficiency aug-
ments inflammatory carcinogenesis. (A) 
Quantification of colonic selenium in WT  
(n = 8), Sepp1+/– (n = 5), and Sepp1–/– (n = 8)  
mice fed a selenium-supplemented (1.0 
PPM) diet. (B) Representative gross colon 
images. (C) Tumor number (tumors per 
mouse) and (D) average tumor size (mm2) 
per mouse (17, WT; 15, Sepp1+/–; 20, Sepp1–/–). 
(E) Representative images of Swiss-rolled 
colons from each genotype (original magni-
fication, ×25). Scale bar: 500 μm. *P < 0.05, 
**P < 0.01, ***P < 0.001, 1-way ANOVA, 
Newman-Keuls multiple comparison test.
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those in WT mice, suggesting that the redox site of SEPP1 contrib-
utes to protection from DNA damage.
Sepp1 haploinsufficiency-driven CAC persists in mice fed nor-
mal selenium diets. Sepp1–/– mice require selenium supplementa-
tion to survive (42); therefore, all of the above experiments were 
conducted in the setting of supranutritional selenium levels. Our 
results indicate that Sepp1 haploinsufficiency augments tumorigen-
esis. We next determined whether Sepp1 heterozygosity would also 
augment tumorigenesis if mice were maintained on a normal sele-
nium diet (0.25 PPM selenium). Compared with WT mice, Sepp1+/– 
mice demonstrated an increase in tumor number, as determined by 
both endoscopy (9.8 ± 1.2 vs. 4.6 ± 0.8 tumors per mouse, P < 0.01; 
Figure 6, A and B) and analysis of tumor burden at sacrifice (11.6 ± 
1.0 vs. 5.5 ± 0.9 tumors per mouse, P < 0.001; Figure 6, C and D), 
and, in general, these tumors were also larger than those observed 
in WT colons (P < 0.05; Figure 6E). When comparing overall sur-
vival of cohorts maintained on a normal selenium diet (0.25 PPM 
selenium) with that of those on a selenium-supplemented diet 
(1.0 PPM selenium), cohorts maintained on the selenium-supple-
mented diet demonstrated a significant survival benefit (P < 0.001; 
Figure 6F). These results may have potential translational implica-
tions, as the 0.25 PPM diet more closely approximates selenium 
levels in the typical Western diet.
Absence of SEPP1 augments stem cell properties and reduces the 
ability of enteroids to survive in response to hydrogen peroxide. SEPP1 
may protect from tumor initiation by preserving genomic integrity.
Mutation of the redox-active selenocysteine in SEPP1 promotes 
inflammatory tumorigenesis. Residues 40–43 of the N-terminal 
domain of SEPP1 comprise a UXXC redox motif that acts as a per-
oxidase (19, 20). As such, SEPP1 may contribute to antioxidant 
activity independent of its roles in selenium transport. In order to 
test whether loss of this antioxidant domain would modify tum-
origenesis, we subjected mice in which the selenocysteine (U) at 
amino acid 40 was mutated to an enzymatically dead serine (S) 
(Sepp1U40S/U40S) to the AOM/DSS protocol. Compared with those in 
WT mice, SEPP1-mutated mice displayed increased tumor num-
ber (7.3 ± 1.1 vs. 3.8 ± 0.7 tumors per mouse, P = 0.02; Figure 5G) 
and tumor size (3.1 ± 0.3 vs. 1.6 ± 0.2 mm2, P = 0.002; Figure 5H). 
This increase in tumorigenesis was likely at least partially depen-
dent upon an increase in crypt proliferation (0.5 ± 0.04 vs. 0.3 ± 
0.02 Ki67+ cells per crypt, P = 0.0009; Figure 5I and Supplemental 
Figure 5A) and intratumoral proliferation (33.5 ± 2.6 vs. 15.2 ± 1.6 
Ki67+ cells per tumor HPF, P < 0.0001; Figure 5J and Supplemen-
tal Figure 5B), compared with those in WT mice, despite a lack 
of change in apoptosis (Supplemental Figure 6, A and B). We did 
note an increase in crypt DNA damage (0.6 ± 0.02 vs. 0.3 ± 0.03 
8-OHdG+ cells per crypt, P < 0.0001; Figure 5K and Supplemental 
Figure 5C) and intratumoral DNA damage (28.7 ± 2.6 vs. 10.8 ± 
1.2 8-OHdG+ cells per tumor HPF, P < 0.0001; Figure 5L and Sup-
plemental Figure 5D) in the SEPP1-mutated mice compared with 
Figure 3. Intratumoral apoptosis and DNA damage are increased in response to complete Sepp1 knockout, and proliferation is increased in Sepp1+/– 
tumors. (A) Quantification of intratumoral apoptosis, as determined by TUNEL+ cells per tumor HPF (original magnification, ×40; 6, WT; 10, Sepp1+/–; 4 
Sepp1–/–), and quantification of cleaved caspase-3 protein normalized to caspase-3 and cleaved PARP protein normalized to β-actin. Quantification is shown 
as fold change relative to WT (n = 6 per group). (B) Quantification of intratumoral proliferation, as determined by Ki67+ cells per tumor HPF (6, WT; 10, 
Sepp1+/–; 4, Sepp1–/–). (C) Quantification of intratumoral DNA damage, as measured by 8-hydroxyguanine+ cells per tumor HPF (6, WT; 10, Sepp1+/–; 4 Sepp1–/–). 
*P < 0.05, **P < 0.01, ***P < 0.001, 1-way ANOVA, Newman-Keuls multiple comparison test.
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regulates oxidative stress and toxicity (43, 44) and, consistent with 
a function in WNT signaling, has been shown to play a role in dif-
ferentiation and stem cell properties (45, 46). Recently, a model for 
epithelial crypt growth has been established based on the isolation 
of stem cells from the small intestinal crypt. From single crypts, 
complex structures can be grown in vitro that closely resemble their 
ex vivo counterparts (enteroids) (47). Using this model system, 
we sought to determine how SEPP1 influences intestinal epithe-
lial biology. Importantly, Sepp1 expression in intestinal organoids 
was similar to expression in both the colon and the brain, a tissue 
known to produce high levels of SEPP1 (48), indicating these cul-
tures would accurately recapitulate an in vivo setting (Figure 7A).
Enteroids can be grown from a single stem cell or complete 
crypts (49), and the “stemness” of enteroids has been measured 
by several growth parameters (50–52). For instance, augmented 
stem cell survival can be measured by an increase in the number of 
crypts that survive plating versus the total number of crypts plated 
(plating efficiency). Furthermore, the percentage of branching 
enteroids or stem spheroids present at certain time points can 
establish the differentiation capacity of the stem cells and the 
extent of stem cell signaling, respectively. Finally, the number of 
branches within each enteroid indicates the ability of the stem cells 
to self-propagate and establish new crypts. To determine whether 
Sepp1 contributes to epithelial cell growth and stem cell function 
at baseline, we analyzed Sepp1–/– enteroids for each of these prop-
erties (plating efficiency: 96.5% ± 2.4% enteroids of total crypts 
plated; 61.5% ± 1.8% branching enteroids; 14.5% ± 0.2% stem 
spheroids; 3.2 ± 0.2 number of branches per branching enteroid; 
Figure 7B) and observed increased stem cell fitness and growth 
abilities compared with those of WT enteroids (plating efficiency: 
65.5% ± 2.0% enteroids of total crypts plated, P < 0.0001; 42.1% ± 
2.4% branching enteroids, P = 0.02; 7.6% ± 0.9% stem spheroids, 
P = 0.002; number of branches per branching enteroid: 1.9 ± 0.1, 
P = 0.003; Figure 7B).
Because SEPP1 serves as a peroxidase in vitro (20), we next 
determined the response of Sepp1–/– enteroids to hydrogen per-
oxide treatment. Analysis of ROS produced after treatment with 
hydrogen peroxide revealed a decreased ability of Sepp1–/– small 
intestine to respond to oxidative stress, as demonstrated by 
increased 6-carboxy-2′,7′-dichlorodihydrofluorescein diacetate 
(carboxy-H2DCFDA) staining intensity (800 μM H2O2: 1.6 ± 0.4 vs. 
3.3 ± 0.4 fold change intensity relative to 0 μM H2O2 WT, P = 0.04; 
Figure 7C); however, there was no change in staining intensity 
of the oxidative-insensitive analog carboxy-DCFDA. Moreover, 
baseline proliferation was increased in Sepp1–/– enteroids (1.0 ± 
0.06 vs. 1.4 ± 0.1 fold change EdU+ cells per crypt area relative to 0 
μM H2O2 WT, P < 0.05; Figure 7D) and, while treatment with hydro-
gen peroxide resulted in decreased Sepp1–/– proliferation compared 
with that of untreated null enteroids (1.4 ± 0.1 vs. 0.9 ± 0.09 fold 
change EdU+ cells per crypt area relative to 0 μM H2O2 Sepp1–/–, 
P < 0.01; Figure 7D), Sepp1–/– enteroids retained increased prolif-
eration compared with that of WT enteroids (0.4 ± 0.09 vs. 0.9 ± 
0.09 fold change EdU+ cells per crypt area relative to 0 μM H2O2 
WT, P < 0.05; Figure 7D). Finally, Sepp1–/– enteroids demonstrated 
decreased survival in response to multiple daily administrations of 
hydrogen peroxide (P = 0.005; Figure 7E). These data indicate that 
Figure 4. SEPP1 regulates protumorigenic M2 macrophage polarization. Quantification of (A) intratumoral total macrophage staining, as determined by 
F4/80+ cells per tumor HPF; (B) M1 macrophage staining, as determined by F4/80+/IL-1β+ cells per tumor HPF; and (C) M2 macrophage staining, as determined 
by F4/80+/ARG1+ cells per tumor HPF (8, WT; 12, Sepp1+/–; 8, Sepp1–/–). (D) Inos (n = 5 per genotype) and Il1b (n = 6 per genotype) and (E) Ym1 mRNA expression 
(n = 6 per group) in WT, Sepp1+/–, and Sepp1–/– in vitro–activated bone marrow macrophages. Graphs demonstrate fold change in expression relative to unstim-
ulated (US) WT macrophages normalized to Gapdh. *P < 0.05, **P < 0.01, ***P < 0.001, 1-way ANOVA, Newman-Keuls multiple comparison test.
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Figure 5. Both the selenium-rich region and the putative antioxidant domain of SEPP1 protect from inflammatory tumorigenesis. (A) Quantification of 
colonic selenium in WT (n = 6) and Sepp1Δ240–361/Δ240–361 (n = 6) mice and (B) number of tumors per mouse (16, WT; 15, Sepp1Δ240–361/Δ240–361). *P < 0.05, ***P < 0.001, 
2-tailed unpaired t test. (C) Percentage of total tumors per genotype with either high-grade dysplasia (HGD) or low-grade dysplasia (LGD) (n = 15 per group,  
***P < 0.001, χ2 contingency analysis) and representative images from tumors of the given genotypes (original magnification, ×40). Scale bar: 200 μm. (D) 
Quantification of intratumoral proliferation, as measured by Ki67+ cells per tumor HPF (12, WT; 17, Sepp1Δ240–361/Δ240–361). (E) Crypt DNA damage, as measured by 
8-hydroxyguanine+ cells per crypt averaged from 20 crypts within each mouse (8, WT; 9, Sepp1Δ240–361/Δ240–361). (F) Intratumoral DNA damage, as measured by 
8-hydroxyguanine+ cells per tumor HPF (8, WT; 17, Sepp1Δ240–361/Δ240–361). (G) Number of tumors and (H) average tumor size within either WT (n = 12) or Sepp1U40S/U40S 
(n = 16) mice. (I) Quantification of crypt proliferation, as measured by Ki67+ cells per crypt averaged from 20 crypts within each mouse (8, WT; 8, Sepp1U40S/U40S);  
(J) intratumoral proliferation, as measured by Ki67+ cells per tumor HPF (11, WT; 19, Sepp1U40S/U40S); (K) crypt DNA damage, as measured by 8-hydroxyguanine+ 
cells per crypt averaged from 20 crypts within each mouse (8, WT; 8, Sepp1U40S/U40S); and (L) intratumoral DNA damage, as measured by 8-hydroxyguanine+ cells 
per tumor HPF (9, WT; 8, Sepp1U40S/U40S). *P < 0.05, **P < 0.01, ***P < 0.001, 2-tailed unpaired t test.
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and MMP-7 upon loss of Sepp1 
expression (Figure 8B). We next 
determined whether SEPP1 loss 
influenced production of other 
oxidative defense genes. First, 
we tested for compensation by 
other selenoproteins at the RNA 
level and did not observe differ-
ences in their message between 
WT and Sepp1–/– tumors. We did, 
however, note significant altera-
tions in several cytochrome 
P450 gene family members as 
well as β-hydroxysteroid dehydrogenase genes (Supplemental Fig-
ure 7), suggesting that other antioxidant genes are upregulated in 
an attempt to compensate for SEPP1 loss.
Discussion
The efficacy of antioxidants as chemopreventive agents of malig-
nancy in the general population has been disappointing. However, 
most studies have been conducted in the setting of relatively nor-
mal selenium levels, which ensures sufficient production of the 
majority of selenoproteins. Patients with IBD are reported to be 
selenium deficient, potentially skewing selenoprotein production. 
Our findings suggest that modifying production of selenoproteins 
(i.e., SEPP1) in patients with IBD may impact cancer risk. Here, 
we show that reduced levels of a major selenoprotein, SEPP1, 
result in increased colonic epithelial stem cell properties, such as 
increased branching and increased presence of stem spheroids as 
well as increased WNT signaling. Reduced expression of SEPP1 
also results in increased DNA damage in response to oxidative 
stress. These SEPP1-dependent phenotypes ultimately contribute 
to an increase in inflammatory tumorigenesis upon loss of either 
the redox-active site or the selenium transport domain of SEPP1 
via its effects on the tumor microenvironment and preservation of 
genomic integrity. These data establish a critical role for SEPP1 in 
intestinal biology, homeostasis, injury response, preservation of 
genomic integrity, and inflammatory carcinogenesis.
absence of SEPP1 increases baseline stem phenotypes and prolif-
eration and compromises the antioxidant potential of enteroids. 
These data are particularly compelling, because they indicate an 
epithelial cell–autonomous role for SEPP1 in processes that would 
likely contribute to tumorigenesis in CAC, a cancer characterized 
by increased microenvironmental oxidative stress.
WNT signaling and oxidative stress gene signatures are altered in 
Sepp1–/– epithelium. Enteroids rely on the addition of growth factors 
EGF, noggin, and R-spondin for growth and differentiation (47). As 
Sepp1–/– enteroids demonstrate increased stem cell properties and 
fitness, we next determined growth factor dependency of Sepp1–/– 
enteroids. Depletion of EGF, noggin, and R-spondin resulted in 
similar decreases in survival in all 3 genotypes, indicating that all 3 
pathways are important for enteroid persistence (Figure 8A).
In order to acquire an unbiased understanding of transcrip-
tome changes within tumors of Sepp1–/– mice, we performed 
RNA sequencing (RNAseq) analysis of tumors isolated from WT 
and Sepp1–/– mice subjected to the AOM/DSS protocol. Ingenuity 
pathway analysis indicated that the WNT pathway was among 
the most significantly altered canonical pathways (Supplemental 
Figure 8), as Sepp1–/– tumors demonstrated increases in Tgfbr3, 
Appl2, Sfrp4, Sfrp5, and Cdh2 expression, among other abnormal-
ities (Table 1 and Supplemental Figure 9). As further validation of 
altered WNT signaling in these tumors, protein analysis demon-
strated increased expression of the WNT targets LEF-1, cyclin D1, 
Figure 6. Sepp1 haploinsufficien-
cy-driven CAC persists in mice 
maintained on normal selenium 
diets. (A) Endoscopic images of 
WT and Sepp1+/– colons after the 
second cycle of DSS administration. 
(B) Quantitative assessment of 
endoscopic tumor burden (11, WT; 
13, Sepp1+/–). **P < 0.01, 2-tailed 
unpaired t test. (C) Gross represen-
tative images of tumors (D) and 
tumor counts at necropsy (11, WT; 
13, Sepp1+/–). ***P < 0.001, 2-tailed 
unpaired t test. (E) Tumor size dis-
tribution. *P < 0.05, unpaired t test 
with Welch’s correction. (F) Survival 
analysis of AOM/DSS-treated mice 
maintained on the indicated diets. 
***P < 0.001, unpaired t test with 
Welch’s correction.
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Because it is a secreted protein, we hypothesize that SEPP1 pro-
vides localized antioxidant benefit to the proximate epithelial 
microenvironment. It was recently shown that SEPP1 antioxidant 
capacity is due, at least in part, to its ability to act as a substrate for 
thioredoxin reductase-1, which catalyzes NADPH oxidation (59). 
From these studies, we postulate that extracellular SEPP1 within 
the near-cell environment may be cooperating with intracellular 
selenoproteins, such as thioredoxin reductase-1, Gpx2, and Gpx4, 
to protect the epithelium from oxidative damage.
Whether selenium supplementation is of potential value 
in reducing cancer risk has been studied. The US case-control 
SELECT study did not demonstrate any clear association between 
serum selenium levels and the risk of recurrent CRC (60), and a 
meta-analysis of intervention trials concluded that oral adminis-
tration of antioxidants, including selenium, was not effective in 
preventing colorectal neoplasia in the general population (61). A 
major limitation of these studies, however, was patient selection, 
as patients in both studies had near-normal selenium levels. Our 
data suggest that targeted supplementation in populations known 
to be selenium deficient might be an effective prevention strategy. 
Patients with IBD are selenium deficient, as measured by both 
plasma selenium and SEPP1 levels (62). Furthermore, the plasma 
concentration of SEPP1 is reduced 53% in patients with Crohn’s 
disease compared with that in healthy controls (63). This suggests 
that patients with IBD are selenium deficient to such an extent 
that selenium supplementation might increase SEPP1 levels and 
subsequently reduce risk of CAC arising from IBD. Indeed, in line 
with the idea of a protective role for selenium supplementation, 
our study demonstrated a significant survival benefit in cohorts of 
mice that were on high selenium diet in comparison to those on 
normal selenium diet when subjected to an AOM/DSS inflamma-
tory carcinogenesis protocol.
Importantly, several SNPs have been identified in SEPP1 that 
might contribute to decreased expression in tumors. For instance, 
SNPs in SEPP1 are associated with decreased plasma SEPP1 in 
men and increased prostate cancer risk (40, 64). Furthermore, 4 
SEPP1 variants have been significantly associated with advanced 
colorectal adenoma risk, including the variant SEPP1 -4166G, 
which exists within the promoter region, 2 loci in the 3′ region 
of SEPP1, and a third locus in the 3′ region of SEPP1, which is 
inversely associated with risk of colorectal adenoma (22). Addi-
tionally, genetic instability has been observed within the (T)17 
repeat motif within the SEPP1 promoter in CRC to the mutator 
phenotype. Thus, this SEPP1 repeat structure may be of functional 
relevance to SEPP1 gene expression and thus modify tumorigen-
esis (65). A mechanism by which some of these polymorphisms 
may alter SEPP1 status is by either altering expression or propor-
tions of SEPP1 isoforms. Several functional polymorphisms in the 
SEPP1 gene have been shown to influence isoform expression, and 
it is thought that increased expression of the 60-kDa isoform of 
SEPP1 may increase selenoprotein synthesis and decrease CRC 
risk (66). Thus, genotyping of SEPP1 in patients with CAC may 
indicate increased responsiveness to selenium supplementation.
In conclusion, we demonstrate a cell-autonomous role for 
SEPP1 in the intestinal epithelium and that its reduction, in vivo, 
augments inflammatory carcinogenesis. These in vivo effects 
occur via independent enzymatic and transport activities. Our 
Induction of several signaling pathways, including NRF2 (11) 
and WNT (10), has been linked to selenium depletion, and there 
is little known about the contribution of SEPP1 to the observed 
alterations in these pathways. We therefore performed an unbi-
ased RNAseq analysis of tumors from WT and Sepp1–/– mice after 
subjecting them to the AOM/DSS protocol. Among the most 
severely altered pathways in response to SEPP1 loss was the WNT 
pathway. While genes were both upregulated and downregulated 
in this pathway, some of particular importance included modula-
tors of WNT signaling, Sfrp4 and Sfrp5; the transcriptional effector 
Lef (also known as Tcf); and the WNT target Mmp7, which we also 
validated at the protein level. Genes that demonstrated increased 
expression included those coding for the TGF-β receptor, N-cad-
herin, and the liver receptor homolog-1 (LRH-1), which is impor-
tant for maintaining stem cell pluripotence during development 
(53). Importantly, ingenuity pathway analysis identified the 
WNT/β-catenin signaling pathway as being stimulated in Sepp1–/– 
tumors. This is of particular importance because SEPP1 is a sele-
nium transporter and selenium deficiency leads to an increase in 
WNT signaling, suggesting that the selenium transport function of 
SEPP1 may contribute to WNT modulation.
The literature has extensively implicated selenium in the 
modulation of immune processes, particularly in relation to mac-
rophage activity (54–56). We noted an increase in M2 polarized 
macrophages in tumors of AOM/DSS-treated Sepp1+/– mice and 
hypothesized that this was due to an effect of SEPP1 on macro-
phage polarization. Isolation of bone marrow macrophages from 
Sepp1+/– mice and subsequent polarization with either IFN-γ and 
LPS (M1) or IL-13 (M2) resulted in deficits in expression of the M1 
markers Inos and Il1b and increased expression of the M2 marker 
Ym1. This altered polarization may contribute to tumorigenesis by 
altering the tumor microenvironment in Sepp1+/– mice. As such, 
SEPP1 may reduce inflammatory tumorigenesis by attenuating 
proinflammatory immune cell activation. This is especially impor-
tant to note when considering the potential positive impact of sele-
nium supplementation on patients with nutritional deficiencies 
due to diseases, such as IBD.
The influence of plasma SEPP1 on delivery of selenium to tar-
get tissues has been extensively studied (36, 57, 58). Our enteroid 
studies demonstrate a role for tissue-produced SEPP1 in intesti-
nal biology, as loss of intestinal epithelial cell–autonomous Sepp1 
affects cellular growth, differentiation, and response to ROS. 
Table 1. Select genes from the WNT signaling pathway that are 
overexpressed in Sepp1–/– tumors
Gene symbol Gene name Fold change P value
Tgfbr3 Transforming growth factor β-3 3.4 5.00E-05
Appl2 Adapter protein containing PH domain, PTB 
domain, and leucine zipper motif 2
2.4 0.0015
Sfrp4 Secreted frizzled-related protein 4 2.7 0.00015
Sfrp5 Secreted frizzled-related protein 5 2.9 5.00E-05
Cdh2 Cadherin-2 2.1 0.00035
Ingenuity pathway analysis of Sepp1–/– tumor RNAseq data relative to 
WT data is shown.
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WT and Sepp1+/– mice were maintained on a normal selenium Torula 
yeast-based diet (0.25 mg selenium [sodium selenite was used] per 
kg). These diets were prepared and pelleted to our specifications 
(42) by Harlan-Teklad. For AOM only experiments (Figure 1A), 8- to 
12-week-old C57BL/6 WT (n = 4), Sepp1+/– (n = 4), or Sepp1–/– (n = 4) mice 
(17, 18) were injected with 12.5 mg/kg AOM (Sigma-Aldrich) intraperi-
toneally. Mice were monitored for tumor burden by endoscopy once 
per month for 6 months and sacrificed 180 days after AOM injection. 
For chronic DSS experiments, 8- to 12-week-old C57BL/6 WT (n = 7), 
Sepp1+/– (n = 10), or Sepp1–/– (n = 10) mice (17, 18) were subjected to three 
5-day cycles of 3% DSS ad libitum, with each cycle being followed by 
a 16-day recovery period (Figure 1B). Mice were monitored for colonic 
studies establish a critical role for SEPP1 in intestinal biology, 
homeostasis, injury response, preservation of genomic integrity, 
and inflammatory carcinogenesis and suggest that SEPP1 could 
serve as a therapeutic target in the prevention of CAC.
Methods
Murine carcinogenesis protocols. Sepp1–/– mice exhibit decreased sur-
vival on standard chow diet (42) and require selenium supplemen-
tation. Therefore, these mice were fed Torula yeast-based diets sup-
plemented with 1.0 mg selenium (sodium selenite was used) per kg. 
Accordingly, to properly control the experiment, WT and Sepp1+/– mice 
were also maintained on an identical diet. In a separate experiment, 
Figure 7. Sepp1–/– enteroids display increased stem cell characteristics as well as ROS production, proliferation, and decreased survival after oxidative 
stress. (A) Sepp1 mRNA expression in tissue isolated from WT mice (n = 3 per group). Fold change expression normalized to Gapdh and relative to colonic 
Sepp1 expression. ***P < 0.001, 1-way ANOVA, Newman-Keuls multiple comparison test. (B) Percentage of surviving enteroids 1 day after plating, percent-
age of branching enteroids and stem spheroids counted 3 days after plating, and average number of branches per branching enteroid at 4 days after plating 
(n = 4 per group per experiment). *P < 0.05, **P < 0.01, ***P < 0.001, 2-tailed unpaired t test. (C) ROS quantification by carboxy-H2DCFDA staining intensity, 
as measured 2 hours after treatment with H2O2. Fold change in intensity relative to WT enteroids treated with 0 μM H2O2 (n = 4 per group). Representative 
images of the single carboxy-H2DCFDA channel and merged carboxy-H2DCFDA and TO-PRO3 channels in WT and Sepp1
–/– enteroids treated with either 0 
μM or 800 μM H2O2 (original magnification, ×100). *P < 0.05, 1-way ANOVA, Newman-Keuls multiple comparison test. (D) Proliferation, as determined by 
EdU+ cells per crypt area within WT and Sepp1–/– enteroids after 2 hours of treatment with either 0 μM or 800 μM H2O2 (n = 4 per group with analysis of 10 
enteroids per genotype) and representative images of EdU staining in WT and Sepp1–/– enteroids after treatment with either 0 μM or 800 μM H2O2 (original 
magnification, ×100). *P < 0.05, **P < 0.01, 1-way ANOVA, Newman-Keuls multiple comparison test. (E) Survival curves for WT, Sepp1+/–, and Sepp1–/– 
enteroids after daily treatment with 400 μM H2O2.
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ion for severity of inflammation (68) and dysplasia on H&E-stained 
“Swiss-rolled” colons by a gastrointestinal pathologist in house.
Immunohistochemistry and immunofluorescence staining. For SEPP1 
and phalloidin staining, colons and small intestines were embedded in 
OCT media and flash frozen in liquid nitrogen. Five-micrometer sec-
tions were cut and SEPP1 staining was performed as described previ-
ously (69). For all other staining, standardized protocols were followed 
to ensure the integrity of the samples for immunohistochemistry/
immunofluorescence applications. In brief, immediately upon sacri-
fice, the colons were harvested, flushed with ice-cold PBS, Swiss rolled 
without delay, and fixed in fresh neutral buffered 10% formalin, which 
was subsequently exchanged for 70% EtOH. Processing was per-
formed at the Vanderbilt University Translational Pathology Shared 
Resource. Five-micrometer sections of paraffin-embedded colons 
were cut, and H&E staining was performed. For immunohistochem-
istry, cut sections were dewaxed, hydrated, and quenched of endoge-
nous peroxidase activity with 0.03% hydrogen peroxide in methanol. 
Antigen retrieval was conducted using Antigen Unmasking Reagent 
(Vector Laboratories Inc.) according to the manufacturer’s instruc-
tions. After blocking, primary antibody was added (α-Ki67 [NeoMark-
ers], 1:1,000; α-ARG1 [Santa Cruz], 1:500; α–IL-1β [R&D Systems], 
injury by endoscopy 4 days into the recovery period after each DSS 
administration. Injury was evaluated based on the MEICS scoring 
system, which grades mucosal thickening, vasculature pattern, gran-
ularity, exudate, and stool consistency (67). For AOM/DSS protocols, 
8- to 12-week-old C57BL/6 WT (n = 13), Sepp1+/– (n = 9), or Sepp1–/– 
(n = 11) mice (17, 18) (constitutional knockout experiment with mice fed 
1.0 mg selenium per kg diet); WT (n = 16) or Sepp1+/– (n = 17) mice (con-
stitutional knockout experiment with mice fed 0.25 mg selenium per 
kg diet); WT (n = 16) or Sepp1Δ240–361/Δ240–361 (n = 14) mice (36) (truncation 
experiments); and WT (n = 12) or Sepp1U40S/U40S (n = 15) (20) mice (redox 
motif mutant experiments) (Table 2) were injected with 12.5 mg/kg 
AOM (Sigma-Aldrich) intraperitoneally. Three days after injection, 
the animals were started on the first of 3 cycles of 3% DSS ad libitum. 
Each cycle lasted 5 days and was followed by a 16-day recovery period. 
During each cycle of recovery, colonoscopy was performed to assess 
injury, tumor multiplicity, and grade (67). All mice were sacrificed on 
day 70, with the exception of cohorts maintained on 0.25 mg selenium 
per kg diet, which were sacrificed on day 52 due to increased mortal-
ity following the third cycle of DSS. All tumor counts and measure-
ments were performed in a blinded fashion under stereo-dissecting 
microscopy. Histologic analysis was performed in a blinded fash-
Figure 8. WNT signaling plays a pivotal role in the Sepp1–/– phenotype. (A) Survival curves in response to growth factor depletion in WT, Sepp1+/–, and 
Sepp1–/– enteroids. (B) Quantification of WNT proteins LEF-1, cyclin D1, and MMP-7 normalized to β-actin. Quantification is shown as fold change relative 
to WT and representative images of blots from 3 individual tumors from each genotype. *P < 0.05, **P < 0.01, ***P < 0.001, 1-way ANOVA, Newman-Keuls 
multiple comparison test.
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production of alternatively activated M2 macrophages, bone marrow 
macrophages were treated with 20 U/ml IL-13 for 12 hours. RNA was 
isolated using the RNEasy Mini Kit (Qiagen). 1 μg RNA was used to 
perform reverse transcription PCR using the iScript cDNA Synthesis 
Kit (Bio-Rad). 1 μl cDNA was used for qRT-PCR analysis of Inos (Bio-
Rad 100-31225), Il1b (RealTimePrimers.com VMPS-3072), and Ym1 
(Bio-Rad 100-31225).
Plasma SEPP1 protein determination. Plasma SEPP1 was mea-
sured by ELISA (36). Plasma samples were diluted in PBS with 0.05% 
Tween-20 containing 2% rat plasma cleared of SEPP1 by monoclonal 
antibody 8F11 as described previously (74).
Small intestinal organoid culturing. Six centimeters of the distal 
small intestine were dissected, flushed with ice-cold PBS, dissected 
into 1-cm pieces, suspended in 5 ml ice-cold PBS, and vortexed 
for 3 seconds. PBS was removed with a pipettor, and the wash was 
repeated. Tissue was transferred to 5 ml chelation buffer (1 mM 
EDTA, made fresh in DPBS) and rocked for 10 minutes at 4°C prior to 
washing twice with 10 ml PBS. 5 ml PBS was added and shaken gen-
tly for 2 minutes. The supernatant from the first shake was poured 
off. 5 ml PBS was added, and the shake was repeated for 2 minutes 
before the supernatant was poured off. 5 ml fresh chelation buffer 
was added, and chelation was performed for 10 minutes at 4°C with 
rocking. Crypts were filtered through a 70-μm filter into a prechilled 
50-ml tube. The filter was rinsed with 5 ml cold shaking buffer (PBS 
with 43.3 mM sucrose and 54.9 mM sorbitol). Complete crypts were 
counted and enough volume for 1,200 crypts was transferred to a 
prechilled 5-ml round-bottomed tube. Crypts were centrifuged at 
150 g for 10 minutes at 4°C. Shaking buffer was aspirated, and crypts 
were resuspended in 50 μl Matrigel (BD Bioscience 356237) per well, 
containing 50 ng/ml EGF (2028-EG-200, R&D Systems), 100 ng/ml 
Noggin (1967-NG-025/CF, R&D Systems), 500 ng/ml R-Spondin 
(3474-RS-050, R&D Systems), and 200 ng/ml WNT3a (GF-160, 
Millipore). Matrigel was overlaid with 500 μl Minigut culture media 
(Advanced DMEM/F12 [12634-010, Invitrogen], l-Glutamine 
[25030, Invitrogen], Pen-Strep [15140-148, Invitrogen], HEPES 
[25-060-CI, Mediatech], N2 Supplement [390155, R&D Systems], 
B27 Supplement [17504044, Invitrogen]). Every 4 days, media were 
replaced with fresh Minigut media plus growth factors.
Whole-mount carboxy-H2DCFDA enteroid staining. Enteroids 
were grown for 4 days after plating. The morning of hydrogen per-
oxide treatment, enteroid media were replaced with fresh Minigut 
media. 0 μM, 400 μM, or 800 μM hydrogen peroxide was added 
directly to media. Two hours after hydrogen peroxide treatment, 
growth media were removed from cells. Cells were treated with 
prewarmed DPBS containing either the probe carboxy-H2DCFDA 
(mp-36103, Invitrogen) or, as a negative control, carboxy-DCFDA 
to provide a final working concentration of 5 mM. Enteroids were 
incubated at 37°C in a cell culture incubator for 1 hour. Loading 
buffer was removed, and cells were returned to prewarmed Minigut 
media. Cells were incubated at 37°C for 15 minutes. Media were 
removed, and enteroids were fixed overnight at 4°C in 2% formalde-
hyde with gentle rocking. Fixative was removed, and enteroids were 
washed twice with DPBS. Enteroids were imaged with a LSM 510 
confocal microscope using the same specifications for imaging of all 
enteroids. ROS were quantified as staining intensity using ImageJ 
Image Analysis software. The graph represents the fold change 
intensity relative to WT enteroids treated with 0 μM hydrogen 
1:40; α-F4/80 [ABd Serotec], 1:1,000; α-8-OHdG [Santa Cruz], 1:500) 
and incubated overnight at 4°C. Isotype-matched antibodies were 
included as negative controls. Identification of intratumoral apoptotic 
cells was conducted using the ApopTag Plus Peroxidase In Situ Apop-
tosis Kit (Chemicon) according to the manufacturer’s protocol. Con-
trol slides were obtained by omitting the terminal transferase enzyme. 
For immunofluorescence staining of proliferation, macrophages, and 
DNA damage, slides were counterstained and mounted with ProLong 
Gold antifade, including DAPI (Invitrogen). Apoptosis, proliferation, 
DNA damage, and M1 and M2 macrophage indices were generated by 
counting either the number of positive cells per HPF (×40 objective) 
within each tumor or the number of positive cells per crypt in 20 crypts 
per mouse by a blinded observer. The average score was then calcu-
lated for each Swiss-rolled colon.
Colonic selenium measurements. The determination of colonic sele-
nium was carried out using a modification of the fluorometric assay 
of Koh and Benson (70) developed by Sheehan and Gao (71). Briefly, 
tissue was digested in nitric and perchloric acids and, after adjustment 
of pH, selenium (as selenite) was complexed with diaminonaphtha-
lene. Selenium-diaminonaphthalene was extracted into cyclohexane, 
and fluorescence was measured in a Perkin-Elmer LS 55 fluorometer 
as described previously (58).
Western blot analysis of apoptosis and WNT pathway proteins. Flash-
frozen sections of colon (n = 6 for each genotype) were lysed in RIPA 
buffer, including 1× protease inhibitor cocktail (Sigma-Aldrich), using 
a rotor homogenizer (Janke & Kunkel IKA Labortechnik Ultra-Turrax 
T25). Protein quantification was performed using a Pierce BCA Pro-
tein Assay Kit (Thermo) according to the manufacturer’s instructions. 
Samples were suspended in loading buffer, boiled, and 40 μg of pro-
tein was run on an SDS-PAGE gel for immunoblotting. The Apoptosis 
Antibody Sampler (Mouse Preferred) Kit (9930, Cell Signaling Tech-
nology) and the WNT Signaling Antibody Sampler Kit (2915, Cell Sig-
naling Technology) were used according to the manufacturer’s proto-
col. Quantification was performed using Odyssey Imaging Software 
and normalized either to total caspase or β-actin.
Bone marrow macrophage polarization and analysis. Bone marrow 
macrophages were isolated and activated as has been previously pub-
lished (72, 73). For the production of classically activated M1 macro-
phages, bone marrow macrophages were primed with 150 U/ml IFN-γ 
for 6 hours and subsequently stimulated with 10 ng/ml LPS. For the 
Table 2. The genotypes of mice subjected to the AOM/DSS 
protocol and the symbols used for each genotype
Nomenclature Mouse description
WT WT N10 C57BL/6
Sepp1+/– Heterozygous SEPP1 knockout (C57BL/6)
Sepp1–/– Homozygous SEPP1 knockout (C57BL/6)
Sepp1Δ240–361/Δ240–361 Homozygous deletion of SEPP1 amino acids 240–361 (C57BL/6)
Sepp1U40S/U40S Homozygous point mutation of position 40 selenocysteine  
to serine in SEPP1 (C57BL/6)
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is shown when all data points are plotted. Percentages of mice dis-
playing altered dysplasia grade were determined using χ2 contingency 
analysis for each grade. All of these analyses were performed using 
GraphPad Prism 5.0c.
Study approval. This study was performed in strict accordance with 
the recommendations in the Guide for the Care and Use of Laboratory 
Animals (8th ed. The National Academies Press. 2011.). The study pro-
tocol was approved by the Institutional Animal Care and Use Commit-
tee at Vanderbilt University (protocol no. M/10-355).
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peroxide (Figure 7C). Error bars represent the SEM for 3 separate 
experiments performed in duplicate.
Whole-mount enteroid proliferation staining. Proliferation was 
determined using the Click-iT EdU cell proliferation assay (C-10337, 
Invitrogen) according to the manufacturer’s instructions. Enteroids 
were grown to 4 days after plating. Enteroid media were replaced with 
fresh Minigut media, and either 0 μM or 800 μM hydrogen perox-
ide was added directly to media. Two hours after hydrogen peroxide 
treatment, media were replaced with fresh Minigut media and a 10 μM 
working solution of EdU was added to each well of the plate. Enteroids 
were incubated for 15 minutes under normal growth conditions. After 
incubation, media were removed and 1 ml of 2% formaldehyde in PBS 
was added to each well and incubated overnight at 4°C. The fixative 
was removed and enteroids were washed twice with 1 ml of 3% BSA 
in PBS. Wash buffer was removed, and 1 ml of 0.5% Triton X-100 in 
PBS was added to each well and incubated at room temperature for 
20 minutes. Click-iT reaction cocktail was prepared, and 0.5 ml was 
added to each well. The wash solution was removed, and enteroids 
were stained with TO-PRO-3 (1:500 in PBS for 15 minutes at room 
temperature). Enteroids were imaged with a LSM 510 confocal micro-
scope using the same specifications for imaging of all enteroids. Pro-
liferation was quantified as EdU+ cells per crypt area where crypt area 
was determined using ImageJ Image Analysis software. The graph 
represents the fold change intensity relative to WT enteroids treated 
with 0 μM hydrogen peroxide (Figure 7D). Error bars represent the 
SEM for 3 separate experiments performed in duplicate.
RNAseq assay and analysis. Tumors were dissected from WT 
and Sepp1–/– mice, and RNA was isolated using the RNEasy Mini Kit 
(Qiagen). RNA integrity was determined using the Experion RNA Std-
Sens Analysis Kit (Bio-Rad). All RNA samples had RNA integrity num-
bers >8 and were deemed suitable for analysis. Initial raw sequencing 
data were aligned to reference mouse genome (mm10) using TopHat 
(version 2.0.8) software with default parameters (75). The Cuffdiff 
software (version 2.1.1) was used to estimate read count for expression 
of each gene and to detect differentially expressed genes. For count-
based gene expression data, Cuffdiff uses the beta negative binomial 
model for each gene in each condition in order to estimate the null 
distribution of its log fold change under the null hypothesis (76). The 
P values from Cuffdiff were adjusted by Benjamini and Hochberg’s 
method to control false discovery rate (77).
Statistics. Analyses comparing 2 groups were analyzed using the 
2-tailed Student’s t test. One-way ANOVA and Newman-Keuls post-
test were used to compare multiple groups. Data are presented as 
the mean ± the SEM in bar graphs, and a line identifying the mean 
 1. Loftus EV Jr, Sandborn WJ. Epidemiology of 
inflammatory bowel disease. Gastroenterol Clin 
North Am. 2002;31(1):1–20.
 2. Abraham C, Cho JH. Inflammatory bowel dis-
ease. N Engl J Med. 2009;361(21):2066–2078.
 3. Roessner A, Kuester D, Malfertheiner P, Schnei-
der-Stock R. Oxidative stress in ulcerative coli-
tis-associated carcinogenesis. Pathol Res Pract. 
2008;204(7):511–524.
 4. Jess T, Simonsen J, Jorgensen KT, Pedersen 
BV, Nielsen NM, Frisch M. Decreasing risk of 
colorectal cancer in patients with inflammatory 
bowel disease over 30 years. Gastroenterology. 
2012;143(2):375–381.
 5. Herrinton LJ, Liu L, Levin TR, Allison JE, 
Lewis JD, Velayos F. Incidence and mortality 
of colorectal adenocarcinoma in persons with 
inflammatory bowel disease from 1998 to 2010. 
Gastroenterology. 2012;143(2):382–389.
 6. Neumann H, Vieth M, Langner C, Neurath MF, 
Mudter J. Cancer risk in IBD: how to diagnose 
and how to manage DALM and ALM. World J 
Gastroenterol. 2011;17(27):3184–3191.
 7. Nguyen GC, Bressler B. A tale of two cohorts: are 
we overestimating the risk of colorectal cancer in 
inflammatory bowel disease? Gastroenterology. 
2012;143(2):288–290.
 8. Rubin DT, et al. Colorectal cancer prevention 
in inflammatory bowel disease and the role 
of 5-aminosalicylic acid: a clinical review and 
update. Inflamm Bowel Dis. 2008;14(2):265–274.
 9. Kipp A, et al. Four selenoproteins, protein biosyn-
thesis, and Wnt signalling are particularly sensi-
tive to limited selenium intake in mouse colon. 
Mol Nutr Food Res. 2009;53(12):1561–1572.
 10. Brigelius-Flohe R, Kipp AP. Selenium in the redox 
regulation of the nrf2 and the wnt pathway. Meth-
ods Enzymol. 2013;527:65–86.
 11. Burk RF, et al. Selenium deficiency activates mouse 
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
2 6 5 9jci.org   Volume 125   Number 7   July 2015
liver Nrf2-ARE but vitamin E deficiency does not. 
Free Radic Biol Med. 2008;44(8):1617–1623.
 12. Kim TH, et al. NRF2 blockade suppresses 
colon tumor angiogenesis by inhibiting hypox-
ia-induced activation of HIF-1α. Cancer Res. 
2011;71(6):2260–2275.
 13. Chang LC, et al. Immunohistochemical study 
of the Nrf2 pathway in colorectal cancer: Nrf2 
expression is closely correlated to Keap1 in the 
tumor and Bach1 in the normal tissue. Appl Immu-
nohistochem Mol Morphol. 2013;21(6):511–517.
 14. Reya T, Clevers H. Wnt signalling in stem cells 
and cancer. Nature. 2005;434(7035):843–850.
 15. Shamberger RJ, Willis CE. Selenium distribution 
and human cancer mortality. CRC Crit Rev Clin 
Lab Sci. 1971;2(2):211–221.
 16. Barrett CW, et al. Dietary selenium deficiency 
exacerbates DSS-induced epithelial injury and 
AOM/DSS-induced tumorigenesis. PLoS One. 
2013;8(7):e67845.
 17. Schomburg L, Schweizer U, Holtmann B, Flohe L, 
Sendtner M, Kohrle J. Gene disruption discloses 
role of selenoprotein P in selenium delivery to 
target tissues. Biochem J. 2003;370(pt 2):397–402.
 18. Hill KE, et al. Deletion of selenoprotein P alters 
distribution of selenium in the mouse. J Biol 
Chem. 2003;278(16):13640–13646.
 19. Burk RF, Hill KE. Selenoprotein P: an extracellu-
lar protein with unique physical characteristics 
and a role in selenium homeostasis. Annu Rev 
Nutr. 2005;25:215–235.
 20. Kurokawa S, et al. Sepp1 forms are N-terminal 
selenoprotein P truncations that have peroxidase 
activity when coupled with thioredoxin reduc-
tase-1. Free Radic Biol Med. 2014;69:67–76.
 21. Al-Taie OH, et al. Expression profiling and genetic 
alterations of the selenoproteins GI-GPx and 
SePP in colorectal carcinogenesis. Nutr Cancer. 
2004;48(1):6–14.
 22. Peters U, et al. Variation in the selenoenzyme 
genes and risk of advanced distal colorectal 
adenoma. Cancer Epidemiol Biomarkers Prev. 
2008;17(5):1144–1154.
 23. Dincer Y, Erzin Y, Himmetoglu S, Gunes KN, Bal 
K, Akcay T. Oxidative DNA damage and antioxi-
dant activity in patients with inflammatory bowel 
disease. Dig Dis Sci. 2007;52(7):1636–1641.
 24. Smith JJ, et al. Experimentally derived metastasis 
gene expression profile predicts recurrence and 
death in patients with colon cancer.  
Gastroenterology. 2010;138(3):958–968.
 25. Pegg AE. Methylation of the O6 position of gua-
nine in DNA is the most likely initiating event in 
carcinogenesis by methylating agents. Cancer 
Invest. 1984;2(3):223–231.
 26. Okayasu I, Ohkusa T, Kajiura K, Kanno J, Saka-
moto S. Promotion of colorectal neoplasia in 
experimental murine ulcerative colitis. Gut. 
1996;39(1):87–92.
 27. Becker C, et al. In vivo imaging of colitis and colon 
cancer development in mice using high resolution 
chromoendoscopy. Gut. 2005;54(7):950–954.
 28. Szatrowski TP, Nathan CF. Production of large 
amounts of hydrogen peroxide by human tumor 
cells. Cancer Res. 1991;51(3):794–798.
 29. Yang WS, et al. Regulation of ferroptotic cancer 
cell death by GPX4. Cell. 2014;156(1):317–331.
 30. Ferguson LR, Karunasinghe N, Zhu S, Wang 
AH. Selenium and its’ role in the main-
tenance of genomic stability. Mutat Res. 
2012;733(1):100–110.
 31. Bera S, De Rosa V, Rachidi W, Diamond AM. 
Does a role for selenium in DNA damage repair 
explain apparent controversies in its use in che-
moprevention? Mutagenesis. 2013;28(2):127–134.
 32. Solinas G, et al. Tumor-conditioned macrophages 
secrete migration-stimulating factor: a new 
marker for M2-polarization, influencing tumor 
cell motility. J Immunol. 2010;185(1):642-652.
 33. Ghassabeh GH, et al. Identification of a common 
gene signature for type II cytokine-associated 
myeloid cells elicited in vivo in different patho-
logic conditions. Blood. 2006;108(2):575–583.
 34. Bosschaerts T, et al. Alternatively activated 
myeloid cells limit pathogenicity associated 
with African trypanosomiasis through the IL-10 
inducible gene selenoprotein P. J Immunol. 
2008;180(9):6168–6175.
 35. Speckmann B, Pinto A, Winter M, Förster I, Sies 
H, Steinbrenner H. Proinflammatory cytokines 
down-regulate intestinal selenoprotein P biosyn-
thesis via NOS2 induction. Free Radic Biol Med. 
2010;49(5):777–785.
 36. Hill KE, et al. The selenium-rich C-terminal 
domain of mouse selenoprotein P is necessary 
for the supply of selenium to brain and testis but 
not for the maintenance of whole body selenium. 
J Biol Chem. 2007;282(15):10972–10980.
 37. Seo YR, Kelley MR, Smith ML. Selenomethi-
onine regulation of p53 by a ref1-dependent 
redox mechanism. Proc Natl Acad Sci U S A. 
2002;99(22):14548–14553.
 38. Jaworska K, et al. A low selenium level is associ-
ated with lung and laryngeal cancers. PLoS One. 
2013;8(3):e59051.
 39. Kasaikina MV, et al. Contrasting roles of dietary 
selenium and selenoproteins in chemically 
induced hepatocarcinogenesis. Carcinogenesis. 
2013;34(5):1089–1095.
 40. Steinbrecher A, et al. Effects of selenium status 
and polymorphisms in selenoprotein genes on 
prostate cancer risk in a prospective study of 
European men. Cancer Epidemiol Biomarkers 
Prev. 2010;19(11):2958–2968.
 41. Connelly-Frost A, Poole C, Satia JA, Kupper LL, 
Millikan RC, Sandler RS. Selenium, folate, and 
colon cancer. Nutr Cancer. 2009;61(2):165–178.
 42. Hill KE, Zhou J, McMahan WJ, Motley AK, Burk 
RF. Neurological dysfunction occurs in mice 
with targeted deletion of the selenoprotein P 
gene. J Nutr. 2004;134(1):157–161.
 43. Xiao W, et al. Selenoprotein P regulates 
1-(4-Chlorophenyl)-benzo-2,5-quinone-induced 
oxidative stress and toxicity in human keratino-
cytes. Free Radic Biol Med. 2013;65:70–77.
 44. Arteel GE, Mostert V, Oubrahim H, Briviba 
K, Abel J, Sies H. Protection by selenoprotein 
P in human plasma against peroxynitrite-
mediated oxidation and nitration. Biol Chem. 
1998;379(8):1201–1205.
 45. Sampson N, et al. ROS signaling by NOX4 drives 
fibroblast-to-myofibroblast differentiation in 
the diseased prostatic stroma. Mol Endocrinol. 
2011;25(3):503–515.
 46. Zhang Y, Chen X. Reducing selenoprotein P 
expression suppresses adipocyte differenti-
ation as a result of increased preadipocyte 
inflammation. Am J Physiol Endocrinol Metab. 
2011;300(1):E77–E85.
 47. Sato T, Clevers H. Growing self-organiz-
ing mini-guts from a single intestinal stem 
cell: mechanism and applications. Science. 
2013;340(6137):1190–1194.
 48. Steinbrenner H, Sies H. Selenium homeostasis 
and antioxidant selenoproteins in brain: implica-
tions for disorders in the central nervous system. 
Arch Biochem Biophys. 2013;536(2):152–157.
 49. Fuller MK, Faulk DM, Sundaram N, Shroyer NF, 
Henning SJ, Helmrath MA. Intestinal crypts 
reproducibly expand in culture. J Surg Res. 
2012;178(1):48–54.
 50. Sato T, et al. Paneth cells constitute the niche 
for Lgr5 stem cells in intestinal crypts. Nature. 
2011;469(7330):415–418.
 51. Durand A, et al. Functional intestinal stem cells 
after Paneth cell ablation induced by the loss 
of transcription factor Math1 (Atoh1). Proc Natl 
Acad Sci U S A. 2012;109(23):8965–8970.
 52. Farin HF, Van Es JH, Clevers H. Redundant sources 
of Wnt regulate intestinal stem cells and promote 
formation of Paneth cells. Gastroenterology. 
2012;143(6):1518–1529 e1517.
 53. Gu P, et al. Orphan nuclear receptor LRH-1 is 
required to maintain Oct4 expression at the epi-
blast stage of embryonic development. Mol Cell 
Biol. 2005;25(9):3492–3505.
 54. Vunta H, Belda BJ, Arner RJ, Channa Reddy 
C, Vanden Heuvel JP, Sandeep Prabhu K. 
Selenium attenuates pro-inflammatory gene 
expression in macrophages. Mol Nutr Food Res. 
2008;52(11):1316–1323.
 55. Carlson BA, et al. Role of selenium-containing 
proteins in T-cell and macrophage function. Proc 
Nutr Soc. 2010;69(3):300–310.
 56. Carlson BA, et al. Selenoproteins regulate 
macrophage invasiveness and extracellular 
matrix-related gene expression. BMC Immunol. 
2009;10:57.
 57. Burk RF, Hill KE. Selenoprotein P. A seleni-
um-rich extracellular glycoprotein. J Nutr. 
1994;124(10):1891–1897.
 58. Burk RF, Hill KE, Motley AK, Austin LM, Nor-
sworthy BK. Deletion of selenoprotein P upreg-
ulates urinary selenium excretion and depresses 
whole-body selenium content. Biochim Biophys 
Acta. 2006;1760(12):1789–1793.
 59. Kurokawa S, et al. Sepp1 forms are N-terminal 
selenoprotein P truncations that have peroxidase 
activity when coupled with thioredoxin reduc-
tase-1. Free Radic Biol Med. 2014;69:67–76.
 60. Lippman SM, et al. Effect of selenium and vita-
min E on risk of prostate cancer and other can-
cers: the Selenium and Vitamin E Cancer Preven-
tion Trial (SELECT). JAMA. 2009;301(1):39–51.
 61. Papaioannou D, et al. Antioxidants in the chemo-
prevention of colorectal cancer and colorectal 
adenomas in the general population: a system-
atic review and meta-analysis. Colorectal Dis. 
2011;13(10):1085–1099.
 62. Ojuawo A, Keith L. The serum concentrations 
of zinc, copper and selenium in children with 
inflammatory bowel disease. Cent Afr J Med. 
2002;48(9):116–119.
 63. Andoh A, et al. Serum selenoprotein-P levels 
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
2 6 6 0 jci.org   Volume 125   Number 7   July 2015
in patients with inflammatory bowel disease. 
Nutrition. 2005;21(5):574–579.
 64. Cooper ML, Adami HO, Gronberg H, Wiklund 
F, Green FR, Rayman MP. Interaction between 
single nucleotide polymorphisms in selenopro-
tein P and mitochondrial superoxide dismutase 
determines prostate cancer risk. Cancer Res. 
2008;68(24):10171–10177.
 65. Al-Taie OH, et al. A complex DNA-repeat 
structure within the selenoprotein P promoter 
contains a functionally relevant polymorphism 
and is genetically unstable under conditions of 
mismatch repair deficiency. Eur J Hum Genet. 
2002;10(9):499–504.
 66. Meplan C, et al. Relative abundance of seleno-
protein P isoforms in human plasma depends on 
genotype, se intake, and cancer status. Antioxid 
Redox Signal. 2009;11(11):2631–2640.
 67. Becker C, Fantini MC, Neurath MF. High res-
olution colonoscopy in live mice. Nat Protoc. 
2006;1(6):2900–2904.
 68. Dieleman LA, et al. Chronic experimental colitis 
induced by dextran sulphate sodium (DSS) is 
characterized by Th1 and Th2 cytokines. Clin Exp 
Immunol. 1998;114(3):385–391.
 69. Olson GE, Winfrey VP, Hill KE, Burk RF. Megalin 
mediates selenoprotein P uptake by kidney 
proximal tubule epithelial cells. J Biol Chem. 
2008;283(11):6854–6860.
 70. Koh TS, Benson TH. Critical re-appraisal of flu-
orometric method for determination of selenium 
in biological materials. J Assoc Off Anal Chem. 
1983;66(4):918–926.
 71. Sheehan TM, Gao M. Simplified fluorometric 
assay of total selenium in plasma and urine. Clin 
Chem. 1990;36(12):2124–2126.
 72. Zhang X, Goncalves R, Mosser DM. The isolation 
and characterization of murine macrophages. 
Curr Protoc Immunol. 2008;Chapter 14:Unit 14.1.
 73. Mosser DM, Zhang X. Activation of murine mac-
rophages. Curr Protoc Immunol. 2008;Chapter 
14:Unit 14.2.
 74. Read R, Bellew T, Yang JG, Hill KE, Palmer IS, 
Burk RF. Selenium and amino acid composition 
of selenoprotein P, the major selenoprotein in rat 
serum. J Biol Chem. 1990;265(29):17899–17905.
 75. Trapnell C, Pachter L, Salzberg SL. TopHat: discov-
ering splice junctions with RNA-Seq. Bioinformatics. 
2009;25(9):1105–1111.
 76. Trapnell C, Hendrickson DG, Sauvageau M, 
Goff L, Rinn JL, Pachter L. Differential analysis 
of gene regulation at transcript resolution with 
RNA-seq. Nat Biotechnol. 2013;31(1):46–53.
 77. Benjamini Y, Drai D, Elmer G, Kafkafi N, 
Golani I. Controlling the false discovery rate 
in behavior genetics research. Behav Brain Res. 
2001;125(1):279–284.
